Genetic variants that increase the risk for complex diseases persist in human populations, despite adverse effects on health and longevity. Life-history theory predicts that such alleles can be maintained by trade-offs arising from pleiotropy, yet direct genomic evidence has been limited. We asked whether disease-associated variants persist because they enhance reproduction, despite costs to health and lifespan. By analysing genome-wide data across 62 diseases, longevity and fertility, we show that disease-risk alleles are, on average, associated with reduced longevity and increased fertility. Moreover, the subset of alleles that increase both fertility and disease risk appear to have been favoured by natural selection over the past 50,000 years. Using Mendelian randomization, we detect a causal effect of genetic liability to disease on longevity, but no robust evidence for a causal effect on fertility; importantly, these estimates remain stable after adjusting for socioeconomic factors. At the individual level, we compared offspring numbers between affected and unaffected individuals with high polygenic disease risk. For most diseases, affected individuals had more children than unaffected ones. But for early-onset diseases, the pattern reverses, indicating reproductive costs of early morbidity. Together, these results support antagonistic pleiotropy and help explain the persistence of disease-risk alleles in human populations.
The persistence of genetic variants that increase susceptibility to complex diseases poses an evolutionary paradox: despite their detrimental health effects, these variants are not eliminated by natural selection. Life-history theory proposes that trade-offs and pleiotropic effects across fitness components may explain the evolutionary maintenance of disease-associated alleles. We hypothesize that certain disease-risk alleles might segregate in the population because they confer reproductive advantages, even at the expense of late-life costs on health and longevity. Leveraging genome-wide association studies, we investigated genetic correlations and pleiotropic relationships between 62 complex diseases, longevity, and fertility. In our study, we estimated fertility by meta-analyzing complementary measures of offspring number and used parental lifespan as a proxy for longevity. We found that 85% of diseases showed negative genetic correlations with longevity, whereas 87% of diseases with significant correlations showed positive associations with fertility. Moreover, most disease-risk variants were associated with reduced longevity, even after accounting for socioeconomic confounders. Fertility-increasing alleles exhibited evolutionary signals consistent with adaptive selection despite having pleiotropic effects on disease-risk. Finally, we compared the number of offspring among individuals with high genetic risk of disease and found that, for most diseases, affected individuals had more offspring than disease-free individuals. However, for early-onset conditions, non-affected individuals exhibited higher fertility, highlighting the reproductive cost of early-onset diseases. These findings support the Antagonistic Pleiotropy theory, showing that alleles that enhance early-life reproductive success can persist despite late-life health costs. By uncovering these evolutionary trade-offs between reproduction, longevity, and disease risk, our study shows how Darwinian selection continues to shape contemporary patterns of human disease susceptibility. Understanding these evolutionary trade-offs can inform public health approaches and help anticipate unintended consequences of targeting disease-related genetic pathways.
PM is a locally aggressive tumor associated with asbestos exposure. Despite legislative efforts to regulate asbestos use, its incidence continues to rise in some parts of the world. Chemotherapy and immunotherapy have improved survival in PM patients, but overall survival remains poor. MTAP loss is frequent in PM and may influence tumor behavior, resulting in a poorer prognosis. MTAP-deficient tumors exhibit unique metabolic vulnerabilities that have stimulated the development of targeted therapeutic strategies in recent years with promising results. The aim of this review is to analyze the prognostic and predictive value of MTAP in PM patients, as well as the outcomes of drugs with potential activity against this target.